Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Dianthus Therapeutics (DNTH) EBIT Margin (2022 - 2025)

Dianthus Therapeutics (DNTH) has 4 years of EBIT Margin data on record, last reported at 10173.74% in Q3 2025.

  • For Q3 2025, EBIT Margin fell 879713.0% year-over-year to 10173.74%; the TTM value through Sep 2025 reached 1756.7%, down 20274.0%, while the annual FY2024 figure was 1633.74%, 7093.0% up from the prior year.
  • EBIT Margin reached 10173.74% in Q3 2025 per DNTH's latest filing, up from 18096.89% in the prior quarter.
  • Across five years, EBIT Margin topped out at 511.88% in Q4 2024 and bottomed at 18096.89% in Q2 2025.
  • Average EBIT Margin over 4 years is 3719.15%, with a median of 1621.06% recorded in 2023.
  • Peak YoY movement for EBIT Margin: surged 252943bps in 2024, then crashed -1690505bps in 2025.
  • A 4-year view of EBIT Margin shows it stood at 923.4% in 2022, then tumbled by -229bps to 3041.31% in 2023, then skyrocketed by 83bps to 511.88% in 2024, then tumbled by -1888bps to 10173.74% in 2025.
  • Per Business Quant database, its latest 3 readings for EBIT Margin were 10173.74% in Q3 2025, 18096.89% in Q2 2025, and 2852.71% in Q1 2025.